Correction to "High affinity antagonists of the vanilloid receptor"

In the above article [Wang Y, Szabo T, Welter JD, Toth A, Tran R, Lee J, Kang SU, Suh YG, Blumberg PM, and Lee J (2002) *Mol Pharmacol* **62:**947–956], please note the following corrections.

Some authors were inadvertently omitted from the article. The complete and correct list of authors and affiliations is as follows:

Yun Wang, Tama Szabo, Jacqueline D. Welter, Attila Toth, Richard Tran, Jiyoun Lee, Sang Uk Kang, Yong-sil Lee, Kyung Hoon Min, Young-Ger Suh, Mi-kyung Park, Hyeung-geun park, Young-Ho Park, Hee-Doo Kim, Uhtaek Oh, Peter M. Blumberg, and Jeewoo Lee

National Cancer Institute, Bethesda, Maryland (Y.W., T.S., J.D.W., A.T., R.T., P.M.B.); College of Pharmacy, Seoul National University, Seoul, Korea (Ji.L., S.U.K., Y.L., K.H.M., Y.-G.S., M.P., H.P., U.O., Je.L.), Sookmyung Women's University, Seoul, Korea (H.-D.K.); Amore Pacific Corp., R&D Center, Yongin, Korea (Y.-H.P.)

On pages 948 (left column, last line) and 954 (right column, line 38), patents WO 02/16317, WO 02/16318, and WO 02/16319 should be cited as references for the series of derivatives that function as rVR1 antagonists. Full information for these patents is provided below:

Suh YG, Oh UT, Kim HD, Lee, JW, Park HG, Park YH, and Yi JB (2002) inventors; Pacific Corporation, assignee. Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same. International patent WO 02/16317 A1. 2002 Feb 28.

Suh YG, Oh UT, Kim HD, Lee JW, Park HG, Park OH, Lee YS, Park YH, Joo YH, Choi JK, Lim KM, Kim SY, Kim JK, Koh HJ, Moh JH, Jeong YS, Yi JB, and Oh YI (2002) inventors; Pacific Corporation, assignee. Novel thiourea derivatives and the pharmaceutical compositions containing the same. International patent WO 02/16318 A1. 2002 Feb 28.

Suh YG,Oh UT, Kim HD, Lee JW, Park HG, Park YH, Yi JB (2002) inventors; Pacific Corporation, assignee. Novel thiourea compounds and the pharmaceutical compositions containing the same. International patent WO 02/16319 A1. 2002 Feb 28.

Finally, KJM429 and JYL1421 correspond to the compound designations MK056 and SC0030 (Fig. 1) in the above patents.

The authors regret these errors and apologize for any confusion or inconvenience they may have caused.



Capsazepine

MK056

SC0030

Fig. 1.